MEN1611 monotherapy showed antitumor activity in several HER2-positive trastuzumab-resistant PIK3CA-mutant PDXs harboring different concomitant genomic aberrations, subsequently inducing tumor-stasis or tumor regression. This evidence concerns the gene ERBB2 and neoplasm.